Index - P/E - EPS (ttm) -2.00 Insider Own 8.79% Shs Outstand 4.16M Perf Week -5.78%
Market Cap 40.36M Forward P/E - EPS next Y -7.86 Insider Trans -0.73% Shs Float 3.71M Perf Month 15.72%
Income 8.52M PEG - EPS next Q -2.24 Inst Own 77.21% Short Float 6.88% Perf Quarter -20.73%
Sales 87.64M P/S 0.46 EPS this Y 88.83% Inst Trans -65.79% Short Ratio 7.09 Perf Half Y -20.92%
Book/sh 10.49 P/B 0.95 EPS next Y -340.84% ROA 9.09% Short Interest 0.26M Perf Year -24.66%
Cash/sh 30.44 P/C 0.33 EPS next 5Y - ROE 29.04% 52W Range 8.25 - 19.43 Perf YTD -9.22%
Dividend Est. - P/FCF - EPS past 5Y 7.97% ROI 10.42% 52W High -48.84% Beta 1.70
Dividend TTM - Quick Ratio 4.37 Sales past 5Y 101.03% Gross Margin 92.70% 52W Low 20.48% ATR (14) 0.55
Dividend Ex-Date - Current Ratio 4.37 EPS Y/Y TTM 91.82% Oper. Margin -8.32% RSI (14) 53.14 Volatility 6.39% 5.49%
Employees 109 Debt/Eq 0.41 Sales Y/Y TTM 88.35% Profit Margin 9.73% Recom 1.40 Target Price 34.60
Option/Short No / Yes LT Debt/Eq 0.09 EPS Q/Q 249.39% Payout - Rel Volume 1.01 Prev Close 9.73
Sales Surprise 548.38% EPS Surprise 320.11% Sales Q/Q 152.15% Earnings Aug 01 BMO Avg Volume 35.99K Price 9.94
SMA20 5.12% SMA50 3.74% SMA200 -12.68% Trades
Volume 36,368 Change 2.16%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-30-24 Initiated Guggenheim
Buy
$19
Jun-17-22 Initiated BMO Capital Markets
Outperform
$7
Jun-09-22 Downgrade William Blair
Outperform → Mkt Perform
Jul-27-20 Resumed BTIG Research
Buy
$16
Apr-03-20 Downgrade Goldman
Buy → Neutral
$24 → $7
Mar-05-20 Initiated Stifel
Buy
$21
Feb-25-20 Initiated William Blair
Outperform
Aug-09-19 Initiated BTIG Research
Buy
$22
Jul-16-19 Initiated H.C. Wainwright
Buy
$21
Apr-22-19 Initiated JP Morgan
Overweight
Apr-22-19 Initiated Jefferies
Buy
Apr-22-19 Initiated Goldman
Buy
Apr-22-19 Initiated Barclays
Overweight
Show Previous Ratings
Sep-04-24 07:01AM
Sep-03-24 07:01AM
Aug-28-24 09:55AM
Aug-12-24 04:32AM
Aug-09-24 07:01AM
08:25AM
Loading…
Aug-01-24 08:25AM
07:22AM
(Associated Press Finance)
07:15AM
Jul-31-24 07:01AM
Jul-29-24 04:15PM
Jul-08-24 07:01AM
Jul-01-24 07:01AM
Jun-27-24 07:01AM
Jun-20-24 07:00AM
Jun-05-24 07:01AM
07:00AM
Loading…
May-30-24 07:00AM
May-29-24 09:55AM
May-17-24 07:00AM
May-13-24 11:53AM
07:22AM
07:08AM
(Associated Press Finance)
07:00AM
May-08-24 08:15AM
May-07-24 04:30PM
08:30AM
May-03-24 09:33AM
May-01-24 07:05AM
Apr-16-24 04:15PM
Apr-11-24 09:55AM
Apr-02-24 09:55AM
06:48AM
Loading…
06:48AM
Mar-27-24 11:53AM
08:10AM
07:07AM
(Associated Press Finance)
06:45AM
Mar-20-24 04:30PM
Mar-19-24 07:00AM
Mar-14-24 08:15AM
Mar-06-24 08:45AM
Mar-01-24 06:30AM
Feb-29-24 04:01PM
09:22AM
Feb-27-24 04:25AM
Feb-20-24 07:00AM
Feb-14-24 07:00AM
Feb-13-24 07:00AM
Feb-12-24 07:00AM
Feb-09-24 07:00AM
Jan-09-24 07:00AM
07:00AM
Dec-13-23 08:20AM
Dec-04-23 07:00AM
Nov-30-23 07:00AM
Nov-28-23 07:00AM
Nov-14-23 08:55AM
Nov-13-23 07:05AM
Nov-10-23 07:00AM
Nov-09-23 07:00AM
Nov-07-23 07:54AM
07:17AM
(Associated Press Finance)
07:00AM
Nov-01-23 07:00AM
Oct-26-23 07:30AM
Oct-23-23 07:00AM
Oct-12-23 08:00AM
Sep-27-23 07:00AM
Sep-12-23 07:00AM
Sep-06-23 07:00AM
Aug-31-23 07:00AM
Aug-22-23 07:32AM
(American City Business Journals)
07:32AM
(American City Business Journals)
Aug-18-23 09:35AM
Aug-15-23 07:04PM
Aug-06-23 08:03AM
Aug-04-23 08:35AM
07:23AM
07:15AM
Aug-01-23 05:00PM
Jul-27-23 07:30AM
Jul-13-23 01:03PM
Jun-22-23 07:00AM
Jun-05-23 07:00AM
May-31-23 07:15AM
May-25-23 07:00AM
May-24-23 08:00AM
May-19-23 07:00AM
May-12-23 05:06PM
May-09-23 08:15AM
07:21AM
07:00AM
May-08-23 04:30PM
May-02-23 07:00AM
Apr-20-23 08:00AM
Apr-19-23 04:22PM
Apr-17-23 07:34AM
Apr-13-23 07:00AM
Mar-27-23 07:00AM
Mar-09-23 08:15AM
07:00AM
Mar-07-23 06:33AM
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Scimeca Dario General Counsel and Secretary Jun 07 '24 Option Exercise 0.00 301 0 6,814 Jun 11 05:13 PM Scimeca Dario General Counsel and Secretary Jun 10 '24 Sale 11.79 93 1,096 6,721 Jun 11 05:13 PM SMITH J. JEFFERSON Chief Research Officer Jun 10 '24 Sale 11.79 50 590 68,559 Jun 11 05:12 PM Scimeca Dario General Counsel and Secretary May 02 '24 Sale 10.32 272 2,807 5,680 May 03 06:33 PM SMITH J. JEFFERSON Chief Research Officer May 02 '24 Sale 10.32 154 1,589 67,613 May 03 06:32 PM List Alan Chief Medical Officer May 02 '24 Sale 10.32 290 2,993 4,488 May 03 06:30 PM Amoroso Michael President and CEO May 02 '24 Sale 10.32 1,526 15,748 13,772 May 03 06:29 PM List Alan Chief Medical Officer Apr 30 '24 Sale 10.03 238 2,386 3,796 Apr 30 06:34 PM Amoroso Michael President and CEO Jan 22 '24 Sale 0.36 137,390 49,460 356,433 Jan 23 07:17 PM Scimeca Dario General Counsel and Secretary Jan 22 '24 Sale 0.36 21,287 7,663 151,028 Jan 23 07:15 PM List Alan Chief Medical Officer Jan 22 '24 Sale 0.36 21,526 7,749 94,982 Jan 23 07:13 PM SMITH J. JEFFERSON Chief Research Officer Jan 23 '24 Sale 0.37 28,000 10,360 1,987,269 Jan 23 07:11 PM Scimeca Dario General Counsel and Secretary Nov 03 '23 Sale 0.40 16,023 6,409 112,970 Nov 06 05:09 PM Amoroso Michael President and CEO Nov 03 '23 Sale 0.40 125,025 50,010 227,103 Nov 06 05:07 PM
Index - P/E - EPS (ttm) -2.55 Insider Own 10.13% Shs Outstand 43.31M Perf Week -0.18%
Market Cap 240.37M Forward P/E - EPS next Y -1.33 Insider Trans -0.20% Shs Float 38.93M Perf Month 25.57%
Income -52.60M PEG - EPS next Q -0.38 Inst Own 70.83% Short Float 7.77% Perf Quarter 29.67%
Sales 0.00M P/S - EPS this Y 41.60% Inst Trans 13.26% Short Ratio 8.39 Perf Half Y -32.73%
Book/sh 1.76 P/B 3.16 EPS next Y 9.64% ROA -56.09% Short Interest 3.03M Perf Year 37.38%
Cash/sh 2.84 P/C 1.95 EPS next 5Y - ROE -127.38% 52W Range 3.05 - 9.01 Perf YTD 10.78%
Dividend Est. - P/FCF - EPS past 5Y 38.92% ROI -56.93% 52W High -38.40% Beta 1.50
Dividend TTM - Quick Ratio 7.48 Sales past 5Y -15.07% Gross Margin 13.31% 52W Low 81.97% ATR (14) 0.31
Dividend Ex-Date - Current Ratio 7.48 EPS Y/Y TTM 30.17% Oper. Margin 0.00% RSI (14) 58.38 Volatility 6.03% 6.20%
Employees 84 Debt/Eq 0.32 Sales Y/Y TTM -100.00% Profit Margin - Recom 1.00 Target Price 15.92
Option/Short Yes / Yes LT Debt/Eq 0.26 EPS Q/Q 71.60% Payout - Rel Volume 0.54 Prev Close 5.63
Sales Surprise -100.00% EPS Surprise 23.98% Sales Q/Q -100.00% Earnings Aug 12 BMO Avg Volume 360.54K Price 5.55
SMA20 5.91% SMA50 11.25% SMA200 2.65% Trades
Volume 193,184 Change -1.42%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-03-24 Initiated H.C. Wainwright
Buy
$15
May-30-24 Initiated Stifel
Buy
$21
Nov-11-20 Upgrade Cantor Fitzgerald
Neutral → Overweight
$4
Sep-18-20 Initiated B. Riley FBR
Buy
$5
Feb-10-20 Initiated SVB Leerink
Outperform
$6
Dec-10-19 Resumed Cantor Fitzgerald
Neutral
$2 → $4
Aug-15-19 Downgrade Maxim Group
Buy → Hold
Aug-12-19 Downgrade Cantor Fitzgerald
Overweight → Neutral
$29 → $2
Jul-26-19 Downgrade Mizuho
Buy → Neutral
$17 → $4
Jun-27-19 Initiated Mizuho
Buy
Oct-12-18 Initiated Mizuho
Buy
$17
Jun-05-18 Initiated Seaport Global Securities
Buy
$29
Nov-08-17 Initiated SunTrust
Buy
$26
Oct-16-17 Reiterated H.C. Wainwright
Buy
$20 → $30
Oct-11-17 Reiterated Cantor Fitzgerald
Overweight
$21 → $34
Oct-10-17 Initiated Citigroup
Buy
$32
Oct-05-17 Reiterated Maxim Group
Buy
$17 → $35
Sep-15-17 Initiated RBC Capital Mkts
Outperform
$23
Jul-18-17 Reiterated Maxim Group
Buy
$14 → $17
Jun-22-17 Resumed Jefferies
Buy
$22
Show Previous Ratings
Sep-03-24 07:30AM
Sep-02-24 07:30AM
Aug-14-24 07:30AM
Aug-13-24 07:30AM
Aug-12-24 07:37AM
(Associated Press Finance) +11.99%
07:30AM
Loading…
07:30AM
Aug-01-24 07:30AM
Jul-11-24 07:30AM
Jul-08-24 07:30AM
Jun-21-24 03:08AM
Jun-03-24 07:30AM
May-28-24 07:30AM
May-16-24 03:01AM
02:17AM
(Thomson Reuters StreetEvents)
May-15-24 12:53PM
07:43AM
Loading…
07:43AM
(Associated Press Finance)
07:30AM
May-07-24 07:30AM
May-03-24 11:19AM
07:30AM
Apr-23-24 02:04PM
08:53AM
07:39AM
07:09AM
Apr-22-24 05:58PM
04:27PM
04:14PM
04:05PM
Apr-01-24 08:30AM
Mar-19-24 06:53AM
05:31AM
Loading…
05:31AM
Mar-18-24 07:30AM
Mar-05-24 07:30AM
Feb-15-24 05:52AM
Feb-01-24 04:05PM
07:30AM
Jan-08-24 07:30AM
Dec-15-23 07:30AM
Nov-27-23 07:30AM
Nov-17-23 10:09AM
Nov-14-23 04:29AM
(Thomson Reuters StreetEvents) -5.56%
Nov-13-23 12:23PM
07:41AM
(Associated Press Finance)
07:30AM
Nov-01-23 07:30AM
Sep-26-23 07:30AM
Sep-12-23 12:48PM
07:30AM
Sep-07-23 07:30AM
Aug-30-23 07:30AM
Aug-11-23 07:41AM
Aug-08-23 08:27AM
07:30AM
Jul-28-23 07:30AM
Jul-19-23 08:30AM
Jul-07-23 08:30AM
Jul-03-23 08:45AM
Jun-09-23 07:30AM
Jun-01-23 07:30AM
May-30-23 08:00AM
(Zacks Small Cap Research)
May-25-23 12:27AM
(Thomson Reuters StreetEvents)
May-22-23 07:30AM
May-16-23 09:00AM
May-13-23 08:15AM
May-11-23 07:54AM
07:30AM
07:00AM
Apr-18-23 07:15AM
(Zacks Small Cap Research)
Apr-10-23 07:30AM
Mar-31-23 06:22AM
Mar-29-23 07:30AM
Mar-24-23 07:30AM
Mar-16-23 07:30AM
Mar-14-23 07:30AM
Nov-14-22 07:30AM
Nov-08-22 02:28PM
Nov-03-22 12:44PM
07:31AM
07:30AM
Oct-19-22 07:30AM
Oct-04-22 07:30AM
Sep-22-22 07:30AM
Sep-13-22 07:30AM
Sep-08-22 08:48AM
Aug-11-22 07:30AM
Jul-20-22 07:30AM
Jun-24-22 10:08AM
Jun-13-22 01:27PM
Jun-10-22 03:30PM
Jun-08-22 01:21PM
Jun-06-22 02:04PM
07:30AM
Jun-01-22 02:25PM
May-31-22 02:27PM
May-25-22 02:29PM
May-23-22 03:32PM
May-19-22 03:02PM
07:30AM
May-18-22 03:12PM
11:47AM
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Alvino Mark Director Jun 18 '24 Sale 4.51 25,890 116,764 36,926 Jun 20 04:30 PM Silverstein Christine Berni Director Jun 18 '24 Sale 4.51 25,821 116,453 62,063 Jun 20 04:30 PM Alland Leila Director May 16 '24 Buy 4.71 11,000 51,799 82,857 May 20 08:30 AM Seshadri Vishwas Chief Executive Officer Apr 25 '24 Buy 3.20 10,000 32,000 538,260 Apr 29 08:30 AM Charles Faith L. Director Apr 26 '24 Buy 3.28 7,550 24,764 78,323 Apr 29 08:30 AM O'Malley Brendan M. SVP, General Counsel Apr 25 '24 Buy 3.24 8,600 27,864 188,718 Apr 26 08:30 AM Vazzano Joseph Walter Chief Financial Officer Apr 25 '24 Buy 3.14 5,608 17,609 233,868 Apr 26 08:30 AM Seshadri Vishwas Chief Executive Officer Feb 06 '24 Buy 4.39 20,000 87,800 528,260 Feb 07 08:30 AM Alvino Mark Director Jan 17 '24 Sale 5.11 7,084 36,199 62,816 Jan 22 04:30 PM Silverstein Christine Berni Director Sep 27 '23 Sale 3.91 6,330 24,721 87,884 Sep 29 04:30 PM Alvino Mark Director Sep 27 '23 Sale 3.91 6,316 24,724 69,900 Sep 29 04:30 PM Charles Faith L. Director Sep 27 '23 Sale 4.91 8,330 40,924 70,773 Sep 29 04:30 PM Alland Leila Director Sep 27 '23 Sale 3.90 7,246 28,270 71,857 Sep 29 04:30 PM Amoroso Michael Director Sep 27 '23 Sale 3.91 5,508 21,542 108,957 Sep 29 04:30 PM Seshadri Vishwas Chief Executive Officer Sep 27 '23 Buy 4.07 20,000 81,400 521,731 Sep 29 07:30 AM Amoroso Michael Director Sep 20 '23 Sale 3.90 327 1,275 114,465 Sep 22 04:05 PM Vazzano Joseph Walter Chief Financial Officer Sep 19 '23 Buy 3.82 3,000 11,458 238,179 Sep 20 09:00 AM O'Malley Brendan M. SVP, General Counsel Sep 18 '23 Buy 3.80 3,000 11,400 187,421 Sep 19 09:00 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
